<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00484198</url>
  </required_header>
  <id_info>
    <org_study_id>CS0011-A-U301</org_study_id>
    <secondary_id>2006-005047-28</secondary_id>
    <nct_id>NCT00484198</nct_id>
  </id_info>
  <brief_title>Study of Rivoglitazone in Type 2 Diabetes Mellitus</brief_title>
  <official_title>A Randomized, Double-blind, Placebo and Active Comparator-Controlled, Parallel-Group Study of the Efficacy and Safety of Rivoglitazone as Monotherapy Treatment of Type 2 Diabetes Mellitus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Daiichi Sankyo, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Daiichi Sankyo, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a 26-week study in subjects with type 2 diabetes currently sub-optimally controlled&#xD;
      by diet and exercise or with non-thiazolidinedione antihyperglycemic monotherapy. The total&#xD;
      duration of a subject's participation will be approximately 30 weeks, including a 2-week&#xD;
      placebo run-in period, a 26-week double-blind treatment period, and a 2-week post-treatment&#xD;
      follow-up period.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 23, 2007</start_date>
  <completion_date type="Actual">February 12, 2009</completion_date>
  <primary_completion_date type="Actual">February 12, 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Hemoglobin A1c at Baseline and Week 26 Endpoint With Last Observation Carried Forward (LOCF) Following Rivoglitazone or Pioglitazone Compared to Placebo as Monotherapy Treatment of Type 2 Diabetes Mellitus</measure>
    <time_frame>Baseline up to week 26 post-dose</time_frame>
    <description>Percentage of hemoglobin A1c (HbA1c) levels are reported.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Hemoglobin A1c From Baseline Through Week 26 Endpoint With Last Observation Carried Forward (LOCF) Following Rivoglitazone or Pioglitazone Compared to Placebo as Monotherapy Treatment of Type 2 Diabetes Mellitus</measure>
    <time_frame>Baseline up to 26 weeks post-dose</time_frame>
    <description>Percent change in hemoglobin (HbA1c) levels are reported. Greater (negative) percent change indicates improvement.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Fasting Plasma Glucose From Baseline Through Week 26 Endpoint With Last Observation Carried Forward (LOCF) Following Rivoglitazone or Pioglitazone Compared to Placebo as Monotherapy Treatment of Type 2 Diabetes Mellitus</measure>
    <time_frame>Baseline up to week 26 post-dose</time_frame>
    <description>Normal fasting plasma glucose (FPG) levels are being reported. Normal FPG levels range from 70-110 mg/dL. Lower FPG values indicates better clinical outcome, ie. improvement in FPG.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Fasting Plasma Glucose From Baseline Through Week 26 Endpoint With Last Observation Carried Forward (LOCF) Following Rivoglitazone or Pioglitazone Compared to Placebo as Monotherapy Treatment of Type 2 Diabetes Mellitus</measure>
    <time_frame>Baseline up to 26 weeks post-dose</time_frame>
    <description>The change in normal fasting plasma glucose (FPG) levels are being reported. A greater (negative) change from baseline indicates an improvement in FPG.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Homeostasis Model Assessment Index for Insulin Resistance At Baseline To Week 26 Endpoint With Last Observation Carried Forward (LOCF) Following Rivoglitazone or Pioglitazone Compared to Placebo as Monotherapy Treatment of Type 2 Diabetes Mellitus</measure>
    <time_frame>Baseline up to week 26 post-dose</time_frame>
    <description>Homeostasis Model Assessment index for Insulin Resistance (HOMA-IR) was calculated as:&#xD;
(fasting insulin concentration [μU/mL] x fasting glucose concentration [mmol/L])/22.5 Low HOMA-IR scores indicate high insulin sensitivity, whereas high HOMA-IR scores indicate low insulin sensitivity (insulin resistance). A normal HOMA-IR score is &lt;2.60, HOMA-IR scores 2.60-3.80 are considered &quot;borderline high&quot;, and HOMA-IR scores &gt;3.80 are considered &quot;high&quot; and have correlations of insulin resistance. High HOMA-IR scores indicate worse outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Homeostasis Model Assessment Index for Insulin Resistance At Baseline To Week 26 Endpoint With Last Observation Carried Forward Following Rivoglitazone or Pioglitazone Compared to Placebo as Monotherapy Treatment of Type 2 Diabetes Mellitus</measure>
    <time_frame>Baseline up to 26 weeks post-dose</time_frame>
    <description>The change in the Homeostasis Model Assessment index for Insulin Resistance (HOMA-IR) was calculated as:&#xD;
(fasting insulin concentration [μU/mL] x fasting glucose concentration [mmol/L])/22.5 Low HOMA-IR scores indicate high insulin sensitivity, whereas high HOMA-IR scores indicate low insulin sensitivity (insulin resistance). A normal HOMA-IR score is &lt;2.60, HOMA-IR scores 2.60-3.80 are considered &quot;borderline high&quot;, and HOMA-IR scores &gt;3.80 are considered &quot;high&quot; and have correlations of insulin resistance. A negative HOMA-IR score indicates an improvement in insulin sensitivity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Cholesterol At Baseline To Week 26 Endpoint With Last Observation Carried Forward (LOCF) Following Rivoglitazone or Pioglitazone Compared to Placebo as Monotherapy Treatment of Type 2 Diabetes Mellitus</measure>
    <time_frame>Baseline up to week 26 post-dose</time_frame>
    <description>Total cholesterol is a measure of the total amount of cholesterol in the blood, including low-density lipoprotein cholesterol (LDL-C) - the &quot;bad&quot; cholesterol, high-density lipoprotein cholesterol (HDL-C) - the &quot;good&quot; cholesterol, and triglycerides. The equation to calculate total cholesterol is: LDL + HDL + (triglycerides/5) = total cholesterol.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change in Total Cholesterol From Baseline to Week 26 Endpoint With Last Observation Carried Forward (LOCF) Following Rivoglitazone or Pioglitazone Compared to Placebo as Monotherapy Treatment of Type 2 Diabetes Mellitus</measure>
    <time_frame>Baseline up to 26 weeks post-dose</time_frame>
    <description>Total cholesterol is a measure of the total amount of cholesterol in the blood, including low-density lipoprotein cholesterol (LDL-C) - the &quot;bad&quot; cholesterol, high-density lipoprotein cholesterol (HDL-C) - the &quot;good&quot; cholesterol, and triglycerides. The equation to calculate total cholesterol is: LDL + HDL + (triglycerides/5) = total cholesterol. Higher percent change in total cholesterol indicates better outcome, ie. improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Triglycerides At Baseline To Week 26 Endpoint With Last Observation Carried Forward (LOCF) Following Rivoglitazone or Pioglitazone Compared to Placebo as Monotherapy Treatment of Type 2 Diabetes Mellitus</measure>
    <time_frame>Baseline up to Week 26 post-dose</time_frame>
    <description>Total Triglycerides (TG) is a measure of the total amount of triglycerides in the blood. The equation to calculate total triglycerides is: (total cholesterol-Low-density Lipoprotein cholesterol (LDL- C) - High-density lipoprotein cholesterol (HDL- C)) x 5 = Total Triglycerides. Normal triglyceride levels are below 150 mg/dL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change in Total Triglycerides From Baseline to Week 26 Endpoint With Last Observation Carried Forward (LOCF) Following Rivoglitazone or Pioglitazone Compared to Placebo as Monotherapy Treatment of Type 2 Diabetes Mellitus</measure>
    <time_frame>Baseline up to 26 weeks post-dose</time_frame>
    <description>Total Triglycerides (TG) is a measure of the total amount of triglycerides in the blood. The equation to calculate total triglycerides is: (total cholesterol-Low-density Lipoprotein cholesterol (LDL- C) - High-density lipoprotein cholesterol (HDL- C)) x 5 = Total Triglycerides. A negative change means better outcome, ie. improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Low-Density Lipoprotein Cholesterol At Baseline To Week 26 Endpoint With Last Observation Carried Forward (LOCF) Following Rivoglitazone or Pioglitazone Compared to Placebo as Monotherapy Treatment of Type 2 Diabetes Mellitus</measure>
    <time_frame>Baseline up to Week 26 post-dose</time_frame>
    <description>Low-density lipoprotein cholesterol (LDL-C), &quot;bad&quot; cholesterol, is a measure of the total amount of low-density lipoprotein cholesterol in the blood. Normal LDL levels are &lt;100 mg/dL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change in Low-Density Lipoprotein Cholesterol From Baseline to Week 26 Endpoint With Last Observation Carried Forward (LOCF) Following Rivoglitazone or Pioglitazone Compared to Placebo as Monotherapy Treatment of Type 2 Diabetes Mellitus</measure>
    <time_frame>Baseline up to 26 weeks post-dose</time_frame>
    <description>Low-density lipoprotein cholesterol (LDL-C), &quot;bad&quot; cholesterol, is a measure of the total amount of low-density lipoprotein cholesterol in the blood. A higher percent change indicates improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>High-Density Lipoprotein Cholesterol At Baseline To Week 26 Endpoint With Last Observation Carried Forward (LOCF) Following Rivoglitazone or Pioglitazone Compared to Placebo as Monotherapy Treatment of Type 2 Diabetes Mellitus</measure>
    <time_frame>Baseline to Week 26 post-dose</time_frame>
    <description>High-density lipoprotein cholesterol (HDL-C), &quot;good&quot; cholesterol, is a measure of the total amount of high-density lipoprotein cholesterol in the blood. Normal HDL levels are &gt;40 mg/dL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change in High-Density Lipoprotein Cholesterol From Baseline to Week 26 Endpoint With Last Observation Carried Forward (LOCF) Following Rivoglitazone or Pioglitazone Compared to Placebo as Monotherapy Treatment of Type 2 Diabetes Mellitus</measure>
    <time_frame>Baseline to 26 weeks post-dose</time_frame>
    <description>High-density lipoprotein cholesterol (HDL-C), &quot;good&quot; cholesterol, is a measure of the total amount of high-density lipoprotein cholesterol in the blood. A higher percent change indicates improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apolipoprotein A-I At Baseline To Week 26 Endpoint With Last Observation Carried Forward (LOCF) Following Rivoglitazone or Pioglitazone Compared to Placebo as Monotherapy Treatment of Type 2 Diabetes Mellitus</measure>
    <time_frame>Baseline to Week 26 post-dose</time_frame>
    <description>Apolipoprotein (Apo) A-I levels, a measure of the total amount of Apolipoprotein (Apo) A-I in the blood, are being reported. Normal Apo A-1 levels range from 120-140 mg/dL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change in Apolipoprotein A-I From Baseline to Week 26 Endpoint With Last Observation Carried Forward (LOCF) Following Rivoglitazone or Pioglitazone Compared to Placebo as Monotherapy Treatment of Type 2 Diabetes Mellitus</measure>
    <time_frame>Baseline up to 26 weeks post-dose</time_frame>
    <description>Apolipoprotein (Apo) A-I is a measure of the total amount of Apolipoprotein (Apo) A-I in the blood. Decreased ApoA-1 levels are associated with poor clinical outcome. A lower percent change in ApoA-1 levels indicates an improvement in clinical outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apolipoprotein B At Baseline To Week 26 Endpoint With Last Observation Carried Forward (LOCF) Following Rivoglitazone or Pioglitazone Compared to Placebo as Monotherapy Treatment of Type 2 Diabetes Mellitus</measure>
    <time_frame>Baseline to Week 26 post-dose</time_frame>
    <description>Apolipoprotein (Apo) B, a measure of the total amount of Apo B in the blood, is being reported. Normal Apo B levels are &lt;100 mg/dL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change in Apolipoprotein B From Baseline to Week 26 Endpoint With Last Observation Carried Forward (LOCF) Following Rivoglitazone or Pioglitazone Compared to Placebo as Monotherapy Treatment of Type 2 Diabetes Mellitus</measure>
    <time_frame>Baseline up to 26 weeks post-dose</time_frame>
    <description>Apolipoprotein (Apo) B, a measure of the total amount of Apo B in the blood, is being reported. A greater (negative) percent change in ApoB levels indicated an improvement in clinical outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hemoglobin A1c at Baseline and Week 52 Extension Period Following Rivoglitazone or Pioglitazone Compared to Placebo as Monotherapy Treatment of Type 2 Diabetes Mellitus</measure>
    <time_frame>Baseline up to Week 52 post-dose</time_frame>
    <description>Percentage of hemoglobin A1c (HbA1c) levels are reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Hemoglobin A1c From Baseline Through Week 52 Extension Period Following Rivoglitazone or Pioglitazone Compared to Placebo as Monotherapy Treatment of Type 2 Diabetes Mellitus</measure>
    <time_frame>Baseline up to 52 weeks post-dose</time_frame>
    <description>Change in hemoglobin (HbA1c) levels are reported. Greater (negative) percent change indicates improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fasting Plasma Glucose From Baseline Through Week 52 Extension Period Following Rivoglitazone or Pioglitazone Compared to Placebo as Monotherapy Treatment of Type 2 Diabetes Mellitus</measure>
    <time_frame>Baseline up to Week 52 post-dose</time_frame>
    <description>Normal fasting plasma glucose (FPG) levels are being reported. Normal FPG levels range from 70-110 mg/dL. Lower FPG values indicates better clinical outcome, ie. improvement in FPG.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Fasting Plasma Glucose From Baseline Through Week 52 Extension Period Following Rivoglitazone or Pioglitazone Compared to Placebo as Monotherapy Treatment of Type 2 Diabetes Mellitus</measure>
    <time_frame>Baseline up to 52 weeks post-dose</time_frame>
    <description>The change in normal fasting plasma glucose (FPG) levels are being reported. A greater (negative) change from baseline indicates an improvement in FPG.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Drug-Related Treatment-Emergent Adverse Events Reported by ≥1% Participants Following Rivoglitazone or Pioglitazone Compared to Placebo as Monotherapy Treatment of Type 2 Diabetes Mellitus</measure>
    <time_frame>Week -2 up to Week 52 post-dose</time_frame>
    <description>Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) that occurred on or after the first dose of double-blind study medication, and ongoing AEs that started prior to the first dose of double-blind study medication and increased in severity on or after the first dose of double-blind study medication.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">1912</enrollment>
  <condition>Type 2 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Rivoglitazone 1.0 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Rivoglitazone 1.5 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Pioglitazone 45 mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pioglitazone</intervention_name>
    <description>45 mg over-encapsulated tablet administered orally, once daily</description>
    <arm_group_label>4</arm_group_label>
    <other_name>Actos</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Rivoglitazone-matching placebo administered as a tablet orally, once daily or a pioglitazone-matching placebo administered as an over-encapsulated tablet orally, once daily capsule</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rivoglitazone</intervention_name>
    <description>1.0 mg tablet administered orally, once daily</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rivoglitazone</intervention_name>
    <description>1.5 mg tablet administered orally, once daily</description>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of type 2 diabetes&#xD;
&#xD;
          -  Male or female at least 18 years of age&#xD;
&#xD;
          -  Hemoglobin A1C &gt; 7% and less or equal to 8.5%&#xD;
&#xD;
          -  Non-fasting C-peptide &gt; 0.5 ng/mL&#xD;
&#xD;
          -  Current monotherapy treatment with stable dose of approved non-Thiazolidinedione (TZD)&#xD;
             antihyperglycemic medication for greater or equal to 3 months prior to screening or&#xD;
&#xD;
          -  Untreated with any antihyperglycemic agent during 2 months prior to screening&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of type 1 diabetes or ketoacidosis&#xD;
&#xD;
          -  History of long-term therapy with insulin&#xD;
&#xD;
          -  Body Mass Index (BMI) &gt; 45 kg/m^2&#xD;
&#xD;
          -  Known history of Congestive Heart Failure (CHF)&#xD;
&#xD;
          -  Impaired hepatic function&#xD;
&#xD;
          -  History of prior treatment failure with, or intolerance of, a TZD&#xD;
&#xD;
          -  Contraindication to treatment with pioglitazone&#xD;
&#xD;
          -  Treatment with fibrates&#xD;
&#xD;
          -  If untreated with oral antihyperglycemic, considered to have failed diet and exercise&#xD;
             modification as the sole treatment for type 2 diabetes&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Global Clinical Leader</last_name>
    <role>Study Director</role>
    <affiliation>Daiichi Sankyo, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Anniston</city>
        <state>Alabama</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hoover</city>
        <state>Alabama</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Muscle Shoals</city>
        <state>Alabama</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hot Springs</city>
        <state>Arkansas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Jonesboro</city>
        <state>Arkansas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Buena Park</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Garden Grove</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Huntington Park</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Paramount</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Walnut Creek</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>West Covina</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>West Hills</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Delray Beach</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Merritt Island</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pembroke Pines</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Honolulu</city>
        <state>Hawaii</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Boise</city>
        <state>Idaho</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Evansville</city>
        <state>Indiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Wichita</city>
        <state>Kansas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Madisonville</city>
        <state>Kentucky</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Slidell</city>
        <state>Louisiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Springfield</city>
        <state>Massachusetts</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Portage</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Southfield</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Voorhees</city>
        <state>New Jersey</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Syracuse</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Morehead City</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Salisbury</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Statesville</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Delaware</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lyndhurst</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Marion</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tulsa</city>
        <state>Oklahoma</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Beaver</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Columbia</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cleveland</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kingsport</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>New Tazewell</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Carrollton</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Conroe</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Corpus Christi</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>El Paso</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Garland</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Irving</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Midland</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Olympia</city>
        <state>Washington</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Loma Verde</city>
        <state>Buenos Aires</state>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Zarate</city>
        <state>Buenos Aires</state>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Vicente</city>
        <state>Cordoba</state>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Feldkirch</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Graz</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Wien</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Santiago</city>
        <state>Providencia</state>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Santiago</city>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Temuco</city>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Horní Město</city>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Karlovy Vary</city>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Prague</city>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Praha</city>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Usti nad Labem</city>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Vysoký Les</city>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Zlin</city>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Znojmo</city>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Aschaffenburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Augsburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bad Oeynhausen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bosenheim</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Dortmund</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Dresden</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Friedrichsthal</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Giessen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Halle</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hamburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kippenheim</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Mainz</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Rehlingen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Riesa</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Saarbrucken</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Saarlouis</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Siegen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Wiesbaden</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Balatonfured</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bekescsaba</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Budapest</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Debrecen</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Eger</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Gyula</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kaposvar</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Szentes</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hyderabad</city>
        <state>Andhra Pradesh</state>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Vijayawada</city>
        <state>Andhra Pradesh</state>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Visakhapatnam</city>
        <state>Andhra Pradesh</state>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Vasanth Nagar</city>
        <state>Bangalore</state>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Mylapore</city>
        <state>Chennai</state>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Shastri Nagar</city>
        <state>Ghaziabad</state>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ahmedabad</city>
        <state>Gujarat</state>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Gandhinagar</city>
        <state>Gujarat</state>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Karnal</city>
        <state>Haryana</state>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sarwa C.</city>
        <state>Jaipur</state>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bangalore</city>
        <state>Karnataka</state>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Belgaum</city>
        <state>Karnataka</state>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Mangalore</city>
        <state>Karnataka</state>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kochi</city>
        <state>Kerala</state>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Indore</city>
        <state>Madhya Pradesh</state>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Mumbai</city>
        <state>Maharashtra</state>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Dhantoli</city>
        <state>Nagpur</state>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ramdaspeth</city>
        <state>Nagpur</state>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Jaipur</city>
        <state>Rajasthan</state>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Coimbatore</city>
        <state>Tamil Nadu</state>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Aligarh</city>
        <state>Uttar Pradesh</state>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Daugavpils</city>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kuldiga</city>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Liepaja</city>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Riga</city>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cuernavaca</city>
        <state>Morelos</state>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Monterrey</city>
        <state>Nuevo Leon</state>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Metepec</city>
        <state>Toluca</state>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Merida</city>
        <state>Yucatan</state>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Aguascalientes</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Durango</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Puebla</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>La Victoria</city>
        <state>Lima</state>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Magdalena del Mar</city>
        <state>Lima</state>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Juan de Miraflores</city>
        <state>Lima</state>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Martin de Porres</city>
        <state>Lima</state>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Monterrico</city>
        <state>Sucro Lima</state>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lima</city>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Rio Piedras</city>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Juan</city>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Villa Fontana</city>
        <zip>00983</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Arad</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Brasov</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bucharest</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Satu Mare</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Targu Mures</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Belgrade</city>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kragujevac</city>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nis</city>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Subotica</city>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Zemun</city>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bratislava</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lucenec</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Moldava nad Bodvou</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nove Mesto nad Vahom</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Považská Bystrica</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Zilina</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Johannesburg</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Port Elizabeth</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Dnipropetrovs'k</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kharkov</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kiev</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lviv</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Simferopol</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Edmonton</city>
        <state>London</state>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sunbury</city>
        <state>Middlesex</state>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Addlestone</city>
        <state>Surrey</state>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Wakefield</city>
        <state>West Yorks</state>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Swindon</city>
        <state>Wiltshire</state>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chippenham</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Austria</country>
    <country>Chile</country>
    <country>Czechia</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>India</country>
    <country>Latvia</country>
    <country>Mexico</country>
    <country>Peru</country>
    <country>Puerto Rico</country>
    <country>Romania</country>
    <country>Serbia</country>
    <country>Slovakia</country>
    <country>South Africa</country>
    <country>Ukraine</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Czech Republic</country>
    <country>Former Serbia and Montenegro</country>
  </removed_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>June 7, 2007</study_first_submitted>
  <study_first_submitted_qc>June 7, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 8, 2007</study_first_posted>
  <results_first_submitted>June 1, 2021</results_first_submitted>
  <results_first_submitted_qc>July 6, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">July 27, 2021</results_first_posted>
  <disposition_first_submitted>February 1, 2010</disposition_first_submitted>
  <disposition_first_submitted_qc>February 1, 2010</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">February 3, 2010</disposition_first_posted>
  <last_update_submitted>July 6, 2021</last_update_submitted>
  <last_update_submitted_qc>July 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Type 2 Diabetes Mellitus</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pioglitazone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>A total of 1,912 participants who met all inclusion criteria and no exclusion criteria were enrolled in the study at 254 sites in Africa, Asia, Europe, North America, and South America.</recruitment_details>
      <pre_assignment_details>During the 2-week stabilization/washout, single-blind, placebo run-in period, participants were to discontinue any previous therapy with oral anti-hyperglycemic agents and were to self-administer single-blind, double-dummy, placebo medication consisting of over-encapsulated pioglitazone-matching placebo tablets and rivoglitazone-matching placebo tablets once daily.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>Participants with type 2 diabetes mellitus who were administered a Rivoglitazone-matching placebo tablet or a Pioglitazone-matching placebo over-encapsulated tablet once daily for 26 weeks.&#xD;
Extension Period:&#xD;
Participants who received Placebo in the base study received Pioglitazone 45 mg once daily for 26-week cycles (Cycle 1 and 2) instead in the extension period.</description>
        </group>
        <group group_id="P2">
          <title>Rivoglitazone 1.0 mg</title>
          <description>Participants with type 2 diabetes mellitus who were administered a Rivoglitazone 1.0 mg tablet once daily for 26 weeks.&#xD;
Extension Period:&#xD;
Participants with type 2 diabetes mellitus who were administered a Rivoglitazone 1.0 mg tablet once daily for 26 week cycles (Cycle 1 and 2).</description>
        </group>
        <group group_id="P3">
          <title>Rivoglitazone 1.5 mg</title>
          <description>Participants with type 2 diabetes mellitus who were administered a Rivoglitazone 1.5 mg tablet once daily for 26 weeks.&#xD;
Extension Period:&#xD;
Participants with type 2 diabetes mellitus who were administered a Rivoglitazone 1.5 mg tablet once daily for 26 weeks cycles (Cycle 1 and 2).</description>
        </group>
        <group group_id="P4">
          <title>Pioglitazone 45 mg</title>
          <description>Participants with type 2 diabetes mellitus who were administered a Pioglitazone 45 mg over-encapsulated tablet once daily for 26 weeks.&#xD;
Extension Period:&#xD;
Participants with type 2 diabetes mellitus who were administered a Pioglitazone 45 mg over-encapsulated tablet once daily for 26 week cycles (Cycle 1 and Cycle 2).</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="137"/>
                <participants group_id="P2" count="274"/>
                <participants group_id="P3" count="750"/>
                <participants group_id="P4" count="751"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="96"/>
                <participants group_id="P2" count="208"/>
                <participants group_id="P3" count="599"/>
                <participants group_id="P4" count="579"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="41"/>
                <participants group_id="P2" count="66"/>
                <participants group_id="P3" count="151"/>
                <participants group_id="P4" count="172"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Participant Withdrew Consent</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="21"/>
                <participants group_id="P3" count="47"/>
                <participants group_id="P4" count="59"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Hyperglycemia Meeting Discontinuation Criteria</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="17"/>
                <participants group_id="P3" count="29"/>
                <participants group_id="P4" count="38"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Therapeutic failure/ lack of efficacy</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="8"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="11"/>
                <participants group_id="P3" count="32"/>
                <participants group_id="P4" count="31"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="8"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="31"/>
                <participants group_id="P4" count="28"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Baseline characteristics were assessed using the All Randomized set.</population>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>Participants with type 2 diabetes mellitus who were administered a Rivoglitazone-matching placebo tablet or a Pioglitazone-matching placebo over-encapsulated tablet once daily for 26 weeks.</description>
        </group>
        <group group_id="B2">
          <title>Rivoglitazone 1.0 mg</title>
          <description>Participants with type 2 diabetes mellitus who were administered a Rivoglitazone 1.0 mg tablet once daily for 26 weeks.</description>
        </group>
        <group group_id="B3">
          <title>Rivoglitazone 1.5 mg</title>
          <description>Participants with type 2 diabetes mellitus who were administered a Rivoglitazone 1.5 mg tablet once daily for 26 weeks.</description>
        </group>
        <group group_id="B4">
          <title>Pioglitazone 45 mg</title>
          <description>Participants with type 2 diabetes mellitus who were administered a Pioglitazone 45 mg over-encapsulated tablet once daily for 26 weeks.</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="137"/>
            <count group_id="B2" value="274"/>
            <count group_id="B3" value="750"/>
            <count group_id="B4" value="751"/>
            <count group_id="B5" value="1912"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="55.4" spread="12.32"/>
                    <measurement group_id="B2" value="55.0" spread="10.51"/>
                    <measurement group_id="B3" value="55.1" spread="10.59"/>
                    <measurement group_id="B4" value="55.0" spread="10.84"/>
                    <measurement group_id="B5" value="55.0" spread="10.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="70"/>
                    <measurement group_id="B2" value="142"/>
                    <measurement group_id="B3" value="368"/>
                    <measurement group_id="B4" value="353"/>
                    <measurement group_id="B5" value="933"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="67"/>
                    <measurement group_id="B2" value="132"/>
                    <measurement group_id="B3" value="382"/>
                    <measurement group_id="B4" value="398"/>
                    <measurement group_id="B5" value="979"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33"/>
                    <measurement group_id="B2" value="59"/>
                    <measurement group_id="B3" value="171"/>
                    <measurement group_id="B4" value="151"/>
                    <measurement group_id="B5" value="414"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="104"/>
                    <measurement group_id="B2" value="215"/>
                    <measurement group_id="B3" value="579"/>
                    <measurement group_id="B4" value="600"/>
                    <measurement group_id="B5" value="1498"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="11"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="42"/>
                    <measurement group_id="B2" value="89"/>
                    <measurement group_id="B3" value="245"/>
                    <measurement group_id="B4" value="243"/>
                    <measurement group_id="B5" value="619"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="33"/>
                    <measurement group_id="B4" value="35"/>
                    <measurement group_id="B5" value="87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="80"/>
                    <measurement group_id="B2" value="147"/>
                    <measurement group_id="B3" value="406"/>
                    <measurement group_id="B4" value="414"/>
                    <measurement group_id="B5" value="1047"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="55"/>
                    <measurement group_id="B4" value="58"/>
                    <measurement group_id="B5" value="142"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Hemoglobin A1c at Baseline and Week 26 Endpoint With Last Observation Carried Forward (LOCF) Following Rivoglitazone or Pioglitazone Compared to Placebo as Monotherapy Treatment of Type 2 Diabetes Mellitus</title>
        <description>Percentage of hemoglobin A1c (HbA1c) levels are reported.</description>
        <time_frame>Baseline up to week 26 post-dose</time_frame>
        <population>Hemoglobin A1c (HbA1c) levels were assessed using the Full Analysis Set.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants with type 2 diabetes mellitus who were administered a Rivoglitazone-matching placebo tablet or a Pioglitazone-matching placebo over-encapsulated tablet once daily for 26 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Rivoglitazone 1.0 mg</title>
            <description>Participants with type 2 diabetes mellitus who were administered a Rivoglitazone 1.0 mg tablet once daily for 26 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Rivoglitazone 1.5mg</title>
            <description>Participants with type 2 diabetes mellitus who were administered a Rivoglitazone 1.5 mg tablet once daily for 26 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Pioglitazone 45 mg</title>
            <description>Participants with type 2 diabetes mellitus who were administered a Pioglitazone 45 mg over-encapsulated tablet once daily for 26 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Hemoglobin A1c at Baseline and Week 26 Endpoint With Last Observation Carried Forward (LOCF) Following Rivoglitazone or Pioglitazone Compared to Placebo as Monotherapy Treatment of Type 2 Diabetes Mellitus</title>
          <description>Percentage of hemoglobin A1c (HbA1c) levels are reported.</description>
          <population>Hemoglobin A1c (HbA1c) levels were assessed using the Full Analysis Set.</population>
          <units>percentage of HbA1c</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="134"/>
                <count group_id="O2" value="266"/>
                <count group_id="O3" value="733"/>
                <count group_id="O4" value="728"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.7" spread="0.55"/>
                    <measurement group_id="O2" value="7.7" spread="0.54"/>
                    <measurement group_id="O3" value="7.7" spread="0.57"/>
                    <measurement group_id="O4" value="7.7" spread="0.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 26</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.0" spread="0.86"/>
                    <measurement group_id="O2" value="7.3" spread="0.94"/>
                    <measurement group_id="O3" value="7.1" spread="0.83"/>
                    <measurement group_id="O4" value="7.2" spread="0.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in Hemoglobin A1c From Baseline Through Week 26 Endpoint With Last Observation Carried Forward (LOCF) Following Rivoglitazone or Pioglitazone Compared to Placebo as Monotherapy Treatment of Type 2 Diabetes Mellitus</title>
        <description>Percent change in hemoglobin (HbA1c) levels are reported. Greater (negative) percent change indicates improvement.</description>
        <time_frame>Baseline up to 26 weeks post-dose</time_frame>
        <population>Change in hemoglobin A1c (HbA1c) levels were assessed using the Full Analysis Set.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants with type 2 diabetes mellitus who were administered a Rivoglitazone-matching placebo tablet or a Pioglitazone-matching placebo over-encapsulated tablet once daily for 26 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Rivoglitazone 1.0 mg</title>
            <description>Participants with type 2 diabetes mellitus who were administered a Rivoglitazone 1.0 mg tablet once daily for 26 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Rivoglitazone 1.5mg</title>
            <description>Participants with type 2 diabetes mellitus who were administered a Rivoglitazone 1.5 mg tablet once daily for 26 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Pioglitazone 45 mg</title>
            <description>Participants with type 2 diabetes mellitus who were administered a Pioglitazone 45 mg over-encapsulated tablet once daily for 26 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Hemoglobin A1c From Baseline Through Week 26 Endpoint With Last Observation Carried Forward (LOCF) Following Rivoglitazone or Pioglitazone Compared to Placebo as Monotherapy Treatment of Type 2 Diabetes Mellitus</title>
          <description>Percent change in hemoglobin (HbA1c) levels are reported. Greater (negative) percent change indicates improvement.</description>
          <population>Change in hemoglobin A1c (HbA1c) levels were assessed using the Full Analysis Set.</population>
          <units>percent change in HbA1c</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="134"/>
                <count group_id="O2" value="266"/>
                <count group_id="O3" value="733"/>
                <count group_id="O4" value="728"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3" spread="0.69"/>
                    <measurement group_id="O2" value="-0.3" spread="0.75"/>
                    <measurement group_id="O3" value="-0.6" spread="0.72"/>
                    <measurement group_id="O4" value="-0.5" spread="0.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Fasting Plasma Glucose From Baseline Through Week 26 Endpoint With Last Observation Carried Forward (LOCF) Following Rivoglitazone or Pioglitazone Compared to Placebo as Monotherapy Treatment of Type 2 Diabetes Mellitus</title>
        <description>Normal fasting plasma glucose (FPG) levels are being reported. Normal FPG levels range from 70-110 mg/dL. Lower FPG values indicates better clinical outcome, ie. improvement in FPG.</description>
        <time_frame>Baseline up to week 26 post-dose</time_frame>
        <population>Fasting plasma glucose levels were assessed in participants with available data in the Full Analysis Set.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants with type 2 diabetes mellitus who were administered a Rivoglitazone-matching placebo tablet or a Pioglitazone-matching placebo over-encapsulated tablet once daily for 26 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Rivoglitazone 1.0 mg</title>
            <description>Participants with type 2 diabetes mellitus who were administered a Rivoglitazone 1.0 mg tablet once daily for 26 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Rivoglitazone 1.5mg</title>
            <description>Participants with type 2 diabetes mellitus who were administered a Rivoglitazone 1.5 mg tablet once daily for 26 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Pioglitazone 45 mg</title>
            <description>Participants with type 2 diabetes mellitus who were administered a Pioglitazone 45 mg over-encapsulated tablet once daily for 26 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Fasting Plasma Glucose From Baseline Through Week 26 Endpoint With Last Observation Carried Forward (LOCF) Following Rivoglitazone or Pioglitazone Compared to Placebo as Monotherapy Treatment of Type 2 Diabetes Mellitus</title>
          <description>Normal fasting plasma glucose (FPG) levels are being reported. Normal FPG levels range from 70-110 mg/dL. Lower FPG values indicates better clinical outcome, ie. improvement in FPG.</description>
          <population>Fasting plasma glucose levels were assessed in participants with available data in the Full Analysis Set.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="133"/>
                <count group_id="O2" value="263"/>
                <count group_id="O3" value="729"/>
                <count group_id="O4" value="721"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="161.1" spread="44.28"/>
                    <measurement group_id="O2" value="159.2" spread="42.33"/>
                    <measurement group_id="O3" value="160.9" spread="40.24"/>
                    <measurement group_id="O4" value="161.9" spread="42.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 26</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="167.5" spread="41.23"/>
                    <measurement group_id="O2" value="136.5" spread="39.73"/>
                    <measurement group_id="O3" value="128.6" spread="35.06"/>
                    <measurement group_id="O4" value="132.3" spread="38.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Fasting Plasma Glucose From Baseline Through Week 26 Endpoint With Last Observation Carried Forward (LOCF) Following Rivoglitazone or Pioglitazone Compared to Placebo as Monotherapy Treatment of Type 2 Diabetes Mellitus</title>
        <description>The change in normal fasting plasma glucose (FPG) levels are being reported. A greater (negative) change from baseline indicates an improvement in FPG.</description>
        <time_frame>Baseline up to 26 weeks post-dose</time_frame>
        <population>Change in fasting plasma glucose levels were assessed in participants with values at both baseline and study endpoint.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants with type 2 diabetes mellitus who were administered a Rivoglitazone-matching placebo tablet or a Pioglitazone-matching placebo over-encapsulated tablet once daily for 26 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Rivoglitazone 1.0 mg</title>
            <description>Participants with type 2 diabetes mellitus who were administered a Rivoglitazone 1.0 mg tablet once daily for 26 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Rivoglitazone 1.5mg</title>
            <description>Participants with type 2 diabetes mellitus who were administered a Rivoglitazone 1.5 mg tablet once daily for 26 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Pioglitazone 45 mg</title>
            <description>Participants with type 2 diabetes mellitus who were administered a Pioglitazone 45 mg over-encapsulated tablet once daily for 26 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Fasting Plasma Glucose From Baseline Through Week 26 Endpoint With Last Observation Carried Forward (LOCF) Following Rivoglitazone or Pioglitazone Compared to Placebo as Monotherapy Treatment of Type 2 Diabetes Mellitus</title>
          <description>The change in normal fasting plasma glucose (FPG) levels are being reported. A greater (negative) change from baseline indicates an improvement in FPG.</description>
          <population>Change in fasting plasma glucose levels were assessed in participants with values at both baseline and study endpoint.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="133"/>
                <count group_id="O2" value="263"/>
                <count group_id="O3" value="729"/>
                <count group_id="O4" value="721"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.1" spread="39.61"/>
                    <measurement group_id="O2" value="-22.1" spread="34.75"/>
                    <measurement group_id="O3" value="-32.4" spread="38.48"/>
                    <measurement group_id="O4" value="-29.5" spread="40.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Homeostasis Model Assessment Index for Insulin Resistance At Baseline To Week 26 Endpoint With Last Observation Carried Forward (LOCF) Following Rivoglitazone or Pioglitazone Compared to Placebo as Monotherapy Treatment of Type 2 Diabetes Mellitus</title>
        <description>Homeostasis Model Assessment index for Insulin Resistance (HOMA-IR) was calculated as:&#xD;
(fasting insulin concentration [μU/mL] x fasting glucose concentration [mmol/L])/22.5 Low HOMA-IR scores indicate high insulin sensitivity, whereas high HOMA-IR scores indicate low insulin sensitivity (insulin resistance). A normal HOMA-IR score is &lt;2.60, HOMA-IR scores 2.60-3.80 are considered &quot;borderline high&quot;, and HOMA-IR scores &gt;3.80 are considered &quot;high&quot; and have correlations of insulin resistance. High HOMA-IR scores indicate worse outcome.</description>
        <time_frame>Baseline up to week 26 post-dose</time_frame>
        <population>Homeostasis Model Assessment Index was assessed in participants with available data in the Full Analysis Set.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants with type 2 diabetes mellitus who were administered a Rivoglitazone-matching placebo tablet or a Pioglitazone-matching placebo over-encapsulated tablet once daily for 26 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Rivoglitazone 1.0 mg</title>
            <description>Participants with type 2 diabetes mellitus who were administered a Rivoglitazone 1.0 mg tablet once daily for 26 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Rivoglitazone 1.5mg</title>
            <description>Participants with type 2 diabetes mellitus who were administered a Rivoglitazone 1.5 mg tablet once daily for 26 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Pioglitazone 45 mg</title>
            <description>Participants with type 2 diabetes mellitus who were administered a Pioglitazone 45 mg over-encapsulated tablet once daily for 26 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Homeostasis Model Assessment Index for Insulin Resistance At Baseline To Week 26 Endpoint With Last Observation Carried Forward (LOCF) Following Rivoglitazone or Pioglitazone Compared to Placebo as Monotherapy Treatment of Type 2 Diabetes Mellitus</title>
          <description>Homeostasis Model Assessment index for Insulin Resistance (HOMA-IR) was calculated as:&#xD;
(fasting insulin concentration [μU/mL] x fasting glucose concentration [mmol/L])/22.5 Low HOMA-IR scores indicate high insulin sensitivity, whereas high HOMA-IR scores indicate low insulin sensitivity (insulin resistance). A normal HOMA-IR score is &lt;2.60, HOMA-IR scores 2.60-3.80 are considered &quot;borderline high&quot;, and HOMA-IR scores &gt;3.80 are considered &quot;high&quot; and have correlations of insulin resistance. High HOMA-IR scores indicate worse outcome.</description>
          <population>Homeostasis Model Assessment Index was assessed in participants with available data in the Full Analysis Set.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="104"/>
                <count group_id="O2" value="243"/>
                <count group_id="O3" value="690"/>
                <count group_id="O4" value="671"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.2" spread="6.98"/>
                    <measurement group_id="O2" value="5.6" spread="4.64"/>
                    <measurement group_id="O3" value="6.0" spread="6.65"/>
                    <measurement group_id="O4" value="6.2" spread="6.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 26</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.8" spread="5.65"/>
                    <measurement group_id="O2" value="4.0" spread="3.78"/>
                    <measurement group_id="O3" value="3.7" spread="4.49"/>
                    <measurement group_id="O4" value="4.1" spread="4.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Homeostasis Model Assessment Index for Insulin Resistance At Baseline To Week 26 Endpoint With Last Observation Carried Forward Following Rivoglitazone or Pioglitazone Compared to Placebo as Monotherapy Treatment of Type 2 Diabetes Mellitus</title>
        <description>The change in the Homeostasis Model Assessment index for Insulin Resistance (HOMA-IR) was calculated as:&#xD;
(fasting insulin concentration [μU/mL] x fasting glucose concentration [mmol/L])/22.5 Low HOMA-IR scores indicate high insulin sensitivity, whereas high HOMA-IR scores indicate low insulin sensitivity (insulin resistance). A normal HOMA-IR score is &lt;2.60, HOMA-IR scores 2.60-3.80 are considered &quot;borderline high&quot;, and HOMA-IR scores &gt;3.80 are considered &quot;high&quot; and have correlations of insulin resistance. A negative HOMA-IR score indicates an improvement in insulin sensitivity.</description>
        <time_frame>Baseline up to 26 weeks post-dose</time_frame>
        <population>Change in Homeostasis Model Assessment Index was assessed in participants with values for baseline and study endpoint.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants with type 2 diabetes mellitus who were administered a Rivoglitazone-matching placebo tablet or a Pioglitazone-matching placebo over-encapsulated tablet once daily for 26 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Rivoglitazone 1.0 mg</title>
            <description>Participants with type 2 diabetes mellitus who were administered a Rivoglitazone 1.0 mg tablet once daily for 26 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Rivoglitazone 1.5mg</title>
            <description>Participants with type 2 diabetes mellitus who were administered a Rivoglitazone 1.5 mg tablet once daily for 26 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Pioglitazone 45 mg</title>
            <description>Participants with type 2 diabetes mellitus who were administered a Pioglitazone 45 mg over-encapsulated tablet once daily for 26 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Homeostasis Model Assessment Index for Insulin Resistance At Baseline To Week 26 Endpoint With Last Observation Carried Forward Following Rivoglitazone or Pioglitazone Compared to Placebo as Monotherapy Treatment of Type 2 Diabetes Mellitus</title>
          <description>The change in the Homeostasis Model Assessment index for Insulin Resistance (HOMA-IR) was calculated as:&#xD;
(fasting insulin concentration [μU/mL] x fasting glucose concentration [mmol/L])/22.5 Low HOMA-IR scores indicate high insulin sensitivity, whereas high HOMA-IR scores indicate low insulin sensitivity (insulin resistance). A normal HOMA-IR score is &lt;2.60, HOMA-IR scores 2.60-3.80 are considered &quot;borderline high&quot;, and HOMA-IR scores &gt;3.80 are considered &quot;high&quot; and have correlations of insulin resistance. A negative HOMA-IR score indicates an improvement in insulin sensitivity.</description>
          <population>Change in Homeostasis Model Assessment Index was assessed in participants with values for baseline and study endpoint.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="104"/>
                <count group_id="O2" value="243"/>
                <count group_id="O3" value="690"/>
                <count group_id="O4" value="671"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4" spread="7.56"/>
                    <measurement group_id="O2" value="-1.5" spread="3.79"/>
                    <measurement group_id="O3" value="-2.3" spread="5.15"/>
                    <measurement group_id="O4" value="-2.2" spread="7.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Cholesterol At Baseline To Week 26 Endpoint With Last Observation Carried Forward (LOCF) Following Rivoglitazone or Pioglitazone Compared to Placebo as Monotherapy Treatment of Type 2 Diabetes Mellitus</title>
        <description>Total cholesterol is a measure of the total amount of cholesterol in the blood, including low-density lipoprotein cholesterol (LDL-C) - the &quot;bad&quot; cholesterol, high-density lipoprotein cholesterol (HDL-C) - the &quot;good&quot; cholesterol, and triglycerides. The equation to calculate total cholesterol is: LDL + HDL + (triglycerides/5) = total cholesterol.</description>
        <time_frame>Baseline up to week 26 post-dose</time_frame>
        <population>Total cholesterol levels were assessed in participants with available data in the Full Analysis Set.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants with type 2 diabetes mellitus who were administered a Rivoglitazone-matching placebo tablet or a Pioglitazone-matching placebo over-encapsulated tablet once daily for 26 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Rivoglitazone 1.0 mg</title>
            <description>Participants with type 2 diabetes mellitus who were administered a Rivoglitazone 1.0 mg tablet once daily for 26 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Rivoglitazone 1.5mg</title>
            <description>Participants with type 2 diabetes mellitus who were administered a Rivoglitazone 1.5 mg tablet once daily for 26 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Pioglitazone 45 mg</title>
            <description>Participants with type 2 diabetes mellitus who were administered a Pioglitazone 45 mg over-encapsulated tablet once daily for 26 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Total Cholesterol At Baseline To Week 26 Endpoint With Last Observation Carried Forward (LOCF) Following Rivoglitazone or Pioglitazone Compared to Placebo as Monotherapy Treatment of Type 2 Diabetes Mellitus</title>
          <description>Total cholesterol is a measure of the total amount of cholesterol in the blood, including low-density lipoprotein cholesterol (LDL-C) - the &quot;bad&quot; cholesterol, high-density lipoprotein cholesterol (HDL-C) - the &quot;good&quot; cholesterol, and triglycerides. The equation to calculate total cholesterol is: LDL + HDL + (triglycerides/5) = total cholesterol.</description>
          <population>Total cholesterol levels were assessed in participants with available data in the Full Analysis Set.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="106"/>
                <count group_id="O2" value="246"/>
                <count group_id="O3" value="694"/>
                <count group_id="O4" value="678"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="190.1" spread="36.23"/>
                    <measurement group_id="O2" value="193.4" spread="38.27"/>
                    <measurement group_id="O3" value="191.6" spread="38.80"/>
                    <measurement group_id="O4" value="189.8" spread="39.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 26</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="191.9" spread="39.60"/>
                    <measurement group_id="O2" value="198.0" spread="40.39"/>
                    <measurement group_id="O3" value="199.1" spread="43.14"/>
                    <measurement group_id="O4" value="194.6" spread="41.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change in Total Cholesterol From Baseline to Week 26 Endpoint With Last Observation Carried Forward (LOCF) Following Rivoglitazone or Pioglitazone Compared to Placebo as Monotherapy Treatment of Type 2 Diabetes Mellitus</title>
        <description>Total cholesterol is a measure of the total amount of cholesterol in the blood, including low-density lipoprotein cholesterol (LDL-C) - the &quot;bad&quot; cholesterol, high-density lipoprotein cholesterol (HDL-C) - the &quot;good&quot; cholesterol, and triglycerides. The equation to calculate total cholesterol is: LDL + HDL + (triglycerides/5) = total cholesterol. Higher percent change in total cholesterol indicates better outcome, ie. improvement.</description>
        <time_frame>Baseline up to 26 weeks post-dose</time_frame>
        <population>Percent change in total cholesterol levels were assessed in participants with values at baseline and study endpoint.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants with type 2 diabetes mellitus who were administered a Rivoglitazone-matching placebo tablet or a Pioglitazone-matching placebo over-encapsulated tablet once daily for 26 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Rivoglitazone 1.0 mg</title>
            <description>Participants with type 2 diabetes mellitus who were administered a Rivoglitazone 1.0 mg tablet once daily for 26 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Rivoglitazone 1.5mg</title>
            <description>Participants with type 2 diabetes mellitus who were administered a Rivoglitazone 1.5 mg tablet once daily for 26 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Pioglitazone 45 mg</title>
            <description>Participants with type 2 diabetes mellitus who were administered a Pioglitazone 45 mg over-encapsulated tablet once daily for 26 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change in Total Cholesterol From Baseline to Week 26 Endpoint With Last Observation Carried Forward (LOCF) Following Rivoglitazone or Pioglitazone Compared to Placebo as Monotherapy Treatment of Type 2 Diabetes Mellitus</title>
          <description>Total cholesterol is a measure of the total amount of cholesterol in the blood, including low-density lipoprotein cholesterol (LDL-C) - the &quot;bad&quot; cholesterol, high-density lipoprotein cholesterol (HDL-C) - the &quot;good&quot; cholesterol, and triglycerides. The equation to calculate total cholesterol is: LDL + HDL + (triglycerides/5) = total cholesterol. Higher percent change in total cholesterol indicates better outcome, ie. improvement.</description>
          <population>Percent change in total cholesterol levels were assessed in participants with values at baseline and study endpoint.</population>
          <units>percent change in total cholesterol</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="106"/>
                <count group_id="O2" value="246"/>
                <count group_id="O3" value="694"/>
                <count group_id="O4" value="678"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.9" spread="13.01"/>
                    <measurement group_id="O2" value="4.0" spread="17.81"/>
                    <measurement group_id="O3" value="5.3" spread="17.49"/>
                    <measurement group_id="O4" value="3.6" spread="16.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Triglycerides At Baseline To Week 26 Endpoint With Last Observation Carried Forward (LOCF) Following Rivoglitazone or Pioglitazone Compared to Placebo as Monotherapy Treatment of Type 2 Diabetes Mellitus</title>
        <description>Total Triglycerides (TG) is a measure of the total amount of triglycerides in the blood. The equation to calculate total triglycerides is: (total cholesterol-Low-density Lipoprotein cholesterol (LDL- C) - High-density lipoprotein cholesterol (HDL- C)) x 5 = Total Triglycerides. Normal triglyceride levels are below 150 mg/dL.</description>
        <time_frame>Baseline up to Week 26 post-dose</time_frame>
        <population>Total triglyceride levels were assessed in participants with available data in the Full Analysis Set.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants with type 2 diabetes mellitus who were administered a Rivoglitazone-matching placebo tablet or a Pioglitazone-matching placebo over-encapsulated tablet once daily for 26 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Rivoglitazone 1.0 mg</title>
            <description>Participants with type 2 diabetes mellitus who were administered a Rivoglitazone 1.0 mg tablet once daily for 26 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Rivoglitazone 1.5mg</title>
            <description>Participants with type 2 diabetes mellitus who were administered a Rivoglitazone 1.5 mg tablet once daily for 26 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Pioglitazone 45 mg</title>
            <description>Participants with type 2 diabetes mellitus who were administered a Pioglitazone 45 mg over-encapsulated tablet once daily for 26 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Total Triglycerides At Baseline To Week 26 Endpoint With Last Observation Carried Forward (LOCF) Following Rivoglitazone or Pioglitazone Compared to Placebo as Monotherapy Treatment of Type 2 Diabetes Mellitus</title>
          <description>Total Triglycerides (TG) is a measure of the total amount of triglycerides in the blood. The equation to calculate total triglycerides is: (total cholesterol-Low-density Lipoprotein cholesterol (LDL- C) - High-density lipoprotein cholesterol (HDL- C)) x 5 = Total Triglycerides. Normal triglyceride levels are below 150 mg/dL.</description>
          <population>Total triglyceride levels were assessed in participants with available data in the Full Analysis Set.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="106"/>
                <count group_id="O2" value="246"/>
                <count group_id="O3" value="694"/>
                <count group_id="O4" value="678"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="185.6" spread="111.25"/>
                    <measurement group_id="O2" value="173.3" spread="104.90"/>
                    <measurement group_id="O3" value="169.5" spread="101.27"/>
                    <measurement group_id="O4" value="175.0" spread="96.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 26</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="170.5" spread="99.17"/>
                    <measurement group_id="O2" value="148.0" spread="91.88"/>
                    <measurement group_id="O3" value="141.0" spread="84.12"/>
                    <measurement group_id="O4" value="152.1" spread="112.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change in Total Triglycerides From Baseline to Week 26 Endpoint With Last Observation Carried Forward (LOCF) Following Rivoglitazone or Pioglitazone Compared to Placebo as Monotherapy Treatment of Type 2 Diabetes Mellitus</title>
        <description>Total Triglycerides (TG) is a measure of the total amount of triglycerides in the blood. The equation to calculate total triglycerides is: (total cholesterol-Low-density Lipoprotein cholesterol (LDL- C) - High-density lipoprotein cholesterol (HDL- C)) x 5 = Total Triglycerides. A negative change means better outcome, ie. improvement.</description>
        <time_frame>Baseline up to 26 weeks post-dose</time_frame>
        <population>Percent change in total triglyceride levels were assessed in participants with values at baseline and study endpoint.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants with type 2 diabetes mellitus who were administered a Rivoglitazone-matching placebo tablet or a Pioglitazone-matching placebo over-encapsulated tablet once daily for 26 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Rivoglitazone 1.0 mg</title>
            <description>Participants with type 2 diabetes mellitus who were administered a Rivoglitazone 1.0 mg tablet once daily for 26 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Rivoglitazone 1.5mg</title>
            <description>Participants with type 2 diabetes mellitus who were administered a Rivoglitazone 1.5 mg tablet once daily for 26 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Pioglitazone 45 mg</title>
            <description>Participants with type 2 diabetes mellitus who were administered a Pioglitazone 45 mg over-encapsulated tablet once daily for 26 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change in Total Triglycerides From Baseline to Week 26 Endpoint With Last Observation Carried Forward (LOCF) Following Rivoglitazone or Pioglitazone Compared to Placebo as Monotherapy Treatment of Type 2 Diabetes Mellitus</title>
          <description>Total Triglycerides (TG) is a measure of the total amount of triglycerides in the blood. The equation to calculate total triglycerides is: (total cholesterol-Low-density Lipoprotein cholesterol (LDL- C) - High-density lipoprotein cholesterol (HDL- C)) x 5 = Total Triglycerides. A negative change means better outcome, ie. improvement.</description>
          <population>Percent change in total triglyceride levels were assessed in participants with values at baseline and study endpoint.</population>
          <units>percent change in total triglycerides</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="106"/>
                <count group_id="O2" value="246"/>
                <count group_id="O3" value="694"/>
                <count group_id="O4" value="678"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.8" spread="26.52"/>
                    <measurement group_id="O2" value="-10.3" spread="32.84"/>
                    <measurement group_id="O3" value="-11.7" spread="34.35"/>
                    <measurement group_id="O4" value="-9.6" spread="45.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Low-Density Lipoprotein Cholesterol At Baseline To Week 26 Endpoint With Last Observation Carried Forward (LOCF) Following Rivoglitazone or Pioglitazone Compared to Placebo as Monotherapy Treatment of Type 2 Diabetes Mellitus</title>
        <description>Low-density lipoprotein cholesterol (LDL-C), &quot;bad&quot; cholesterol, is a measure of the total amount of low-density lipoprotein cholesterol in the blood. Normal LDL levels are &lt;100 mg/dL.</description>
        <time_frame>Baseline up to Week 26 post-dose</time_frame>
        <population>Low-density lipoprotein cholesterol levels were assessed in participants with available data in the Full Analysis Set.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants with type 2 diabetes mellitus who were administered a Rivoglitazone-matching placebo tablet or a Pioglitazone-matching placebo over-encapsulated tablet once daily for 26 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Rivoglitazone 1.0 mg</title>
            <description>Participants with type 2 diabetes mellitus who were administered a Rivoglitazone 1.0 mg tablet once daily for 26 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Rivoglitazone 1.5mg</title>
            <description>Participants with type 2 diabetes mellitus who were administered a Rivoglitazone 1.5 mg tablet once daily for 26 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Pioglitazone 45 mg</title>
            <description>Participants with type 2 diabetes mellitus who were administered a Pioglitazone 45 mg over-encapsulated tablet once daily for 26 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Low-Density Lipoprotein Cholesterol At Baseline To Week 26 Endpoint With Last Observation Carried Forward (LOCF) Following Rivoglitazone or Pioglitazone Compared to Placebo as Monotherapy Treatment of Type 2 Diabetes Mellitus</title>
          <description>Low-density lipoprotein cholesterol (LDL-C), &quot;bad&quot; cholesterol, is a measure of the total amount of low-density lipoprotein cholesterol in the blood. Normal LDL levels are &lt;100 mg/dL.</description>
          <population>Low-density lipoprotein cholesterol levels were assessed in participants with available data in the Full Analysis Set.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="106"/>
                <count group_id="O2" value="246"/>
                <count group_id="O3" value="694"/>
                <count group_id="O4" value="674"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="108.5" spread="29.68"/>
                    <measurement group_id="O2" value="112.8" spread="32.37"/>
                    <measurement group_id="O3" value="112.1" spread="32.35"/>
                    <measurement group_id="O4" value="110.5" spread="33.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 26</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="111.8" spread="31.37"/>
                    <measurement group_id="O2" value="118.0" spread="34.19"/>
                    <measurement group_id="O3" value="118.7" spread="36.99"/>
                    <measurement group_id="O4" value="115.0" spread="36.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change in Low-Density Lipoprotein Cholesterol From Baseline to Week 26 Endpoint With Last Observation Carried Forward (LOCF) Following Rivoglitazone or Pioglitazone Compared to Placebo as Monotherapy Treatment of Type 2 Diabetes Mellitus</title>
        <description>Low-density lipoprotein cholesterol (LDL-C), &quot;bad&quot; cholesterol, is a measure of the total amount of low-density lipoprotein cholesterol in the blood. A higher percent change indicates improvement.</description>
        <time_frame>Baseline up to 26 weeks post-dose</time_frame>
        <population>Percent change in low-density lipoprotein cholesterol was assessed in participants with values at baseline and study endpoint.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants with type 2 diabetes mellitus who were administered a Rivoglitazone-matching placebo tablet or a Pioglitazone-matching placebo over-encapsulated tablet once daily for 26 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Rivoglitazone 1.0 mg</title>
            <description>Participants with type 2 diabetes mellitus who were administered a Rivoglitazone 1.0 mg tablet once daily for 26 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Rivoglitazone 1.5mg</title>
            <description>Participants with type 2 diabetes mellitus who were administered a Rivoglitazone 1.5 mg tablet once daily for 26 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Pioglitazone 45 mg</title>
            <description>Participants with type 2 diabetes mellitus who were administered a Pioglitazone 45 mg over-encapsulated tablet once daily for 26 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change in Low-Density Lipoprotein Cholesterol From Baseline to Week 26 Endpoint With Last Observation Carried Forward (LOCF) Following Rivoglitazone or Pioglitazone Compared to Placebo as Monotherapy Treatment of Type 2 Diabetes Mellitus</title>
          <description>Low-density lipoprotein cholesterol (LDL-C), &quot;bad&quot; cholesterol, is a measure of the total amount of low-density lipoprotein cholesterol in the blood. A higher percent change indicates improvement.</description>
          <population>Percent change in low-density lipoprotein cholesterol was assessed in participants with values at baseline and study endpoint.</population>
          <units>percent change in LDL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="106"/>
                <count group_id="O2" value="246"/>
                <count group_id="O3" value="694"/>
                <count group_id="O4" value="674"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.4" spread="18.56"/>
                    <measurement group_id="O2" value="9.3" spread="32.91"/>
                    <measurement group_id="O3" value="9.6" spread="30.02"/>
                    <measurement group_id="O4" value="7.3" spread="32.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>High-Density Lipoprotein Cholesterol At Baseline To Week 26 Endpoint With Last Observation Carried Forward (LOCF) Following Rivoglitazone or Pioglitazone Compared to Placebo as Monotherapy Treatment of Type 2 Diabetes Mellitus</title>
        <description>High-density lipoprotein cholesterol (HDL-C), &quot;good&quot; cholesterol, is a measure of the total amount of high-density lipoprotein cholesterol in the blood. Normal HDL levels are &gt;40 mg/dL.</description>
        <time_frame>Baseline to Week 26 post-dose</time_frame>
        <population>High-density lipoprotein cholesterol was assessed in participants with available data in the Full Analysis Set.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants with type 2 diabetes mellitus who were administered a Rivoglitazone-matching placebo tablet or a Pioglitazone-matching placebo over-encapsulated tablet once daily for 26 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Rivoglitazone 1.0 mg</title>
            <description>Participants with type 2 diabetes mellitus who were administered a Rivoglitazone 1.0 mg tablet once daily for 26 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Rivoglitazone 1.5mg</title>
            <description>Participants with type 2 diabetes mellitus who were administered a Rivoglitazone 1.5 mg tablet once daily for 26 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Pioglitazone 45 mg</title>
            <description>Participants with type 2 diabetes mellitus who were administered a Pioglitazone 45 mg over-encapsulated tablet once daily for 26 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>High-Density Lipoprotein Cholesterol At Baseline To Week 26 Endpoint With Last Observation Carried Forward (LOCF) Following Rivoglitazone or Pioglitazone Compared to Placebo as Monotherapy Treatment of Type 2 Diabetes Mellitus</title>
          <description>High-density lipoprotein cholesterol (HDL-C), &quot;good&quot; cholesterol, is a measure of the total amount of high-density lipoprotein cholesterol in the blood. Normal HDL levels are &gt;40 mg/dL.</description>
          <population>High-density lipoprotein cholesterol was assessed in participants with available data in the Full Analysis Set.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="106"/>
                <count group_id="O2" value="246"/>
                <count group_id="O3" value="694"/>
                <count group_id="O4" value="675"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.3" spread="11.73"/>
                    <measurement group_id="O2" value="46.0" spread="12.49"/>
                    <measurement group_id="O3" value="45.8" spread="11.46"/>
                    <measurement group_id="O4" value="44.7" spread="10.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 26</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.6" spread="11.46"/>
                    <measurement group_id="O2" value="50.4" spread="14.84"/>
                    <measurement group_id="O3" value="52.0" spread="14.72"/>
                    <measurement group_id="O4" value="49.7" spread="12.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change in High-Density Lipoprotein Cholesterol From Baseline to Week 26 Endpoint With Last Observation Carried Forward (LOCF) Following Rivoglitazone or Pioglitazone Compared to Placebo as Monotherapy Treatment of Type 2 Diabetes Mellitus</title>
        <description>High-density lipoprotein cholesterol (HDL-C), &quot;good&quot; cholesterol, is a measure of the total amount of high-density lipoprotein cholesterol in the blood. A higher percent change indicates improvement.</description>
        <time_frame>Baseline to 26 weeks post-dose</time_frame>
        <population>Percent change in high-density lipoprotein cholesterol was assessed in participants with values at baseline and study endpoint.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants with type 2 diabetes mellitus who were administered a Rivoglitazone-matching placebo tablet or a Pioglitazone-matching placebo over-encapsulated tablet once daily for 26 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Rivoglitazone 1.0 mg</title>
            <description>Participants with type 2 diabetes mellitus who were administered a Rivoglitazone 1.0 mg tablet once daily for 26 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Rivoglitazone 1.5mg</title>
            <description>Participants with type 2 diabetes mellitus who were administered a Rivoglitazone 1.5 mg tablet once daily for 26 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Pioglitazone 45 mg</title>
            <description>Participants with type 2 diabetes mellitus who were administered a Pioglitazone 45 mg over-encapsulated tablet once daily for 26 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change in High-Density Lipoprotein Cholesterol From Baseline to Week 26 Endpoint With Last Observation Carried Forward (LOCF) Following Rivoglitazone or Pioglitazone Compared to Placebo as Monotherapy Treatment of Type 2 Diabetes Mellitus</title>
          <description>High-density lipoprotein cholesterol (HDL-C), &quot;good&quot; cholesterol, is a measure of the total amount of high-density lipoprotein cholesterol in the blood. A higher percent change indicates improvement.</description>
          <population>Percent change in high-density lipoprotein cholesterol was assessed in participants with values at baseline and study endpoint.</population>
          <units>percent change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="106"/>
                <count group_id="O2" value="246"/>
                <count group_id="O3" value="694"/>
                <count group_id="O4" value="675"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.7" spread="14.30"/>
                    <measurement group_id="O2" value="10.3" spread="18.15"/>
                    <measurement group_id="O3" value="14.8" spread="22.65"/>
                    <measurement group_id="O4" value="12.3" spread="21.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Apolipoprotein A-I At Baseline To Week 26 Endpoint With Last Observation Carried Forward (LOCF) Following Rivoglitazone or Pioglitazone Compared to Placebo as Monotherapy Treatment of Type 2 Diabetes Mellitus</title>
        <description>Apolipoprotein (Apo) A-I levels, a measure of the total amount of Apolipoprotein (Apo) A-I in the blood, are being reported. Normal Apo A-1 levels range from 120-140 mg/dL.</description>
        <time_frame>Baseline to Week 26 post-dose</time_frame>
        <population>Apolipoprotein A-I was assessed in participants with available data in the Full Analysis Set.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants with type 2 diabetes mellitus who were administered a Rivoglitazone-matching placebo tablet or a Pioglitazone-matching placebo over-encapsulated tablet once daily for 26 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Rivoglitazone 1.0 mg</title>
            <description>Participants with type 2 diabetes mellitus who were administered a Rivoglitazone 1.0 mg tablet once daily for 26 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Rivoglitazone 1.5mg</title>
            <description>Participants with type 2 diabetes mellitus who were administered a Rivoglitazone 1.5 mg tablet once daily for 26 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Pioglitazone 45 mg</title>
            <description>Participants with type 2 diabetes mellitus who were administered a Pioglitazone 45 mg over-encapsulated tablet once daily for 26 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Apolipoprotein A-I At Baseline To Week 26 Endpoint With Last Observation Carried Forward (LOCF) Following Rivoglitazone or Pioglitazone Compared to Placebo as Monotherapy Treatment of Type 2 Diabetes Mellitus</title>
          <description>Apolipoprotein (Apo) A-I levels, a measure of the total amount of Apolipoprotein (Apo) A-I in the blood, are being reported. Normal Apo A-1 levels range from 120-140 mg/dL.</description>
          <population>Apolipoprotein A-I was assessed in participants with available data in the Full Analysis Set.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="105"/>
                <count group_id="O2" value="245"/>
                <count group_id="O3" value="691"/>
                <count group_id="O4" value="677"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="145.3" spread="25.11"/>
                    <measurement group_id="O2" value="145.7" spread="27.60"/>
                    <measurement group_id="O3" value="145.2" spread="24.31"/>
                    <measurement group_id="O4" value="143.6" spread="22.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 26</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="146.2" spread="26.39"/>
                    <measurement group_id="O2" value="146.4" spread="29.52"/>
                    <measurement group_id="O3" value="145.9" spread="27.37"/>
                    <measurement group_id="O4" value="143.9" spread="24.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change in Apolipoprotein A-I From Baseline to Week 26 Endpoint With Last Observation Carried Forward (LOCF) Following Rivoglitazone or Pioglitazone Compared to Placebo as Monotherapy Treatment of Type 2 Diabetes Mellitus</title>
        <description>Apolipoprotein (Apo) A-I is a measure of the total amount of Apolipoprotein (Apo) A-I in the blood. Decreased ApoA-1 levels are associated with poor clinical outcome. A lower percent change in ApoA-1 levels indicates an improvement in clinical outcome.</description>
        <time_frame>Baseline up to 26 weeks post-dose</time_frame>
        <population>Percent change in apolipoprotein A-I was assessed in participants with values at baseline and study endpoint.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants with type 2 diabetes mellitus who were administered a Rivoglitazone-matching placebo tablet or a Pioglitazone-matching placebo over-encapsulated tablet once daily for 26 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Rivoglitazone 1.0 mg</title>
            <description>Participants with type 2 diabetes mellitus who were administered a Rivoglitazone 1.0 mg tablet once daily for 26 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Rivoglitazone 1.5mg</title>
            <description>Participants with type 2 diabetes mellitus who were administered a Rivoglitazone 1.5 mg tablet once daily for 26 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Pioglitazone 45 mg</title>
            <description>Participants with type 2 diabetes mellitus who were administered a Pioglitazone 45 mg over-encapsulated tablet once daily for 26 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change in Apolipoprotein A-I From Baseline to Week 26 Endpoint With Last Observation Carried Forward (LOCF) Following Rivoglitazone or Pioglitazone Compared to Placebo as Monotherapy Treatment of Type 2 Diabetes Mellitus</title>
          <description>Apolipoprotein (Apo) A-I is a measure of the total amount of Apolipoprotein (Apo) A-I in the blood. Decreased ApoA-1 levels are associated with poor clinical outcome. A lower percent change in ApoA-1 levels indicates an improvement in clinical outcome.</description>
          <population>Percent change in apolipoprotein A-I was assessed in participants with values at baseline and study endpoint.</population>
          <units>percent change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="105"/>
                <count group_id="O2" value="245"/>
                <count group_id="O3" value="691"/>
                <count group_id="O4" value="677"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0" spread="12.22"/>
                    <measurement group_id="O2" value="1.0" spread="12.88"/>
                    <measurement group_id="O3" value="0.9" spread="13.18"/>
                    <measurement group_id="O4" value="0.8" spread="13.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Apolipoprotein B At Baseline To Week 26 Endpoint With Last Observation Carried Forward (LOCF) Following Rivoglitazone or Pioglitazone Compared to Placebo as Monotherapy Treatment of Type 2 Diabetes Mellitus</title>
        <description>Apolipoprotein (Apo) B, a measure of the total amount of Apo B in the blood, is being reported. Normal Apo B levels are &lt;100 mg/dL.</description>
        <time_frame>Baseline to Week 26 post-dose</time_frame>
        <population>Apolipoprotein B was assessed in participants with available data in the Full Analysis Set.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants with type 2 diabetes mellitus who were administered a Rivoglitazone-matching placebo tablet or a Pioglitazone-matching placebo over-encapsulated tablet once daily for 26 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Rivoglitazone 1.0 mg</title>
            <description>Participants with type 2 diabetes mellitus who were administered a Rivoglitazone 1.0 mg tablet once daily for 26 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Rivoglitazone 1.5mg</title>
            <description>Participants with type 2 diabetes mellitus who were administered a Rivoglitazone 1.5 mg tablet once daily for 26 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Pioglitazone 45 mg</title>
            <description>Participants with type 2 diabetes mellitus who were administered a Pioglitazone 45 mg over-encapsulated tablet once daily for 26 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Apolipoprotein B At Baseline To Week 26 Endpoint With Last Observation Carried Forward (LOCF) Following Rivoglitazone or Pioglitazone Compared to Placebo as Monotherapy Treatment of Type 2 Diabetes Mellitus</title>
          <description>Apolipoprotein (Apo) B, a measure of the total amount of Apo B in the blood, is being reported. Normal Apo B levels are &lt;100 mg/dL.</description>
          <population>Apolipoprotein B was assessed in participants with available data in the Full Analysis Set.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="105"/>
                <count group_id="O2" value="245"/>
                <count group_id="O3" value="691"/>
                <count group_id="O4" value="677"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="112.8" spread="25.24"/>
                    <measurement group_id="O2" value="116.1" spread="26.49"/>
                    <measurement group_id="O3" value="114.6" spread="26.88"/>
                    <measurement group_id="O4" value="114.3" spread="27.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 26</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="115.3" spread="26.50"/>
                    <measurement group_id="O2" value="113.6" spread="28.60"/>
                    <measurement group_id="O3" value="111.5" spread="30.29"/>
                    <measurement group_id="O4" value="110.3" spread="28.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change in Apolipoprotein B From Baseline to Week 26 Endpoint With Last Observation Carried Forward (LOCF) Following Rivoglitazone or Pioglitazone Compared to Placebo as Monotherapy Treatment of Type 2 Diabetes Mellitus</title>
        <description>Apolipoprotein (Apo) B, a measure of the total amount of Apo B in the blood, is being reported. A greater (negative) percent change in ApoB levels indicated an improvement in clinical outcome.</description>
        <time_frame>Baseline up to 26 weeks post-dose</time_frame>
        <population>Apolipoprotein B was assessed in participants with values at baseline and study endpoint.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants with type 2 diabetes mellitus who were administered a Rivoglitazone-matching placebo tablet or a Pioglitazone-matching placebo over-encapsulated tablet once daily for 26 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Rivoglitazone 1.0 mg</title>
            <description>Participants with type 2 diabetes mellitus who were administered a Rivoglitazone 1.0 mg tablet once daily for 26 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Rivoglitazone 1.5mg</title>
            <description>Participants with type 2 diabetes mellitus who were administered a Rivoglitazone 1.5 mg tablet once daily for 26 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Pioglitazone 45 mg</title>
            <description>Participants with type 2 diabetes mellitus who were administered a Pioglitazone 45 mg over-encapsulated tablet once daily for 26 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change in Apolipoprotein B From Baseline to Week 26 Endpoint With Last Observation Carried Forward (LOCF) Following Rivoglitazone or Pioglitazone Compared to Placebo as Monotherapy Treatment of Type 2 Diabetes Mellitus</title>
          <description>Apolipoprotein (Apo) B, a measure of the total amount of Apo B in the blood, is being reported. A greater (negative) percent change in ApoB levels indicated an improvement in clinical outcome.</description>
          <population>Apolipoprotein B was assessed in participants with values at baseline and study endpoint.</population>
          <units>percent change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="105"/>
                <count group_id="O2" value="245"/>
                <count group_id="O3" value="691"/>
                <count group_id="O4" value="677"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.0" spread="14.83"/>
                    <measurement group_id="O2" value="-0.4" spread="19.46"/>
                    <measurement group_id="O3" value="-1.1" spread="21.24"/>
                    <measurement group_id="O4" value="-2.5" spread="18.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Hemoglobin A1c at Baseline and Week 52 Extension Period Following Rivoglitazone or Pioglitazone Compared to Placebo as Monotherapy Treatment of Type 2 Diabetes Mellitus</title>
        <description>Percentage of hemoglobin A1c (HbA1c) levels are reported.</description>
        <time_frame>Baseline up to Week 52 post-dose</time_frame>
        <population>Hemoglobin A1c levels were assessed using the Study Extension Set.</population>
        <group_list>
          <group group_id="O1">
            <title>Rivoglitazone 1.0 mg</title>
            <description>Participants with type 2 diabetes mellitus who were administered a Rivoglitazone 1.0 mg tablet once daily for 26 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Rivoglitazone 1.5mg</title>
            <description>Participants with type 2 diabetes mellitus who were administered a Rivoglitazone 1.5 mg tablet once daily for 26 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Pioglitazone 45 mg</title>
            <description>Participants with type 2 diabetes mellitus who were administered a Pioglitazone 45 mg over-encapsulated tablet once daily for 26 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Placebo/Pioglitazone 45 mg</title>
            <description>Participants with type 2 diabetes mellitus who were administered a Rivoglitazone-matching placebo tablet or a Pioglitazone-matching placebo over-encapsulated tablet once daily for 26 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Hemoglobin A1c at Baseline and Week 52 Extension Period Following Rivoglitazone or Pioglitazone Compared to Placebo as Monotherapy Treatment of Type 2 Diabetes Mellitus</title>
          <description>Percentage of hemoglobin A1c (HbA1c) levels are reported.</description>
          <population>Hemoglobin A1c levels were assessed using the Study Extension Set.</population>
          <units>percentage of HbA1c</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="66"/>
                <count group_id="O2" value="200"/>
                <count group_id="O3" value="194"/>
                <count group_id="O4" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="66"/>
                    <count group_id="O2" value="200"/>
                    <count group_id="O3" value="194"/>
                    <count group_id="O4" value="27"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.5" spread="0.46"/>
                    <measurement group_id="O2" value="7.6" spread="0.53"/>
                    <measurement group_id="O3" value="7.6" spread="0.51"/>
                    <measurement group_id="O4" value="7.4" spread="0.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="27"/>
                    <count group_id="O2" value="65"/>
                    <count group_id="O3" value="54"/>
                    <count group_id="O4" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.0" spread="0.72"/>
                    <measurement group_id="O2" value="6.9" spread="0.60"/>
                    <measurement group_id="O3" value="6.9" spread="0.58"/>
                    <measurement group_id="O4" value="7.0" spread="0.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Hemoglobin A1c From Baseline Through Week 52 Extension Period Following Rivoglitazone or Pioglitazone Compared to Placebo as Monotherapy Treatment of Type 2 Diabetes Mellitus</title>
        <description>Change in hemoglobin (HbA1c) levels are reported. Greater (negative) percent change indicates improvement.</description>
        <time_frame>Baseline up to 52 weeks post-dose</time_frame>
        <population>Hemoglobin A1c was assessed in participants with values at baseline and the extension visit at the end of Cycle 1.</population>
        <group_list>
          <group group_id="O1">
            <title>Rivoglitazone 1.0 mg</title>
            <description>Participants with type 2 diabetes mellitus who were administered a Rivoglitazone 1.0 mg tablet once daily for 26 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Rivoglitazone 1.5mg</title>
            <description>Participants with type 2 diabetes mellitus who were administered a Rivoglitazone 1.5 mg tablet once daily for 26 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Pioglitazone 45 mg</title>
            <description>Participants with type 2 diabetes mellitus who were administered a Pioglitazone 45 mg over-encapsulated tablet once daily for 26 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Placebo/ Pioglitazone 45 mg</title>
            <description>Participants with type 2 diabetes mellitus who were administered a Rivoglitazone-matching placebo tablet or a Pioglitazone-matching placebo over-encapsulated tablet once daily for 26 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Hemoglobin A1c From Baseline Through Week 52 Extension Period Following Rivoglitazone or Pioglitazone Compared to Placebo as Monotherapy Treatment of Type 2 Diabetes Mellitus</title>
          <description>Change in hemoglobin (HbA1c) levels are reported. Greater (negative) percent change indicates improvement.</description>
          <population>Hemoglobin A1c was assessed in participants with values at baseline and the extension visit at the end of Cycle 1.</population>
          <units>percent change in HbA1c</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="65"/>
                <count group_id="O3" value="54"/>
                <count group_id="O4" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.5" spread="0.69"/>
                    <measurement group_id="O2" value="-0.7" spread="0.57"/>
                    <measurement group_id="O3" value="-0.7" spread="0.67"/>
                    <measurement group_id="O4" value="-0.4" spread="0.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Fasting Plasma Glucose From Baseline Through Week 52 Extension Period Following Rivoglitazone or Pioglitazone Compared to Placebo as Monotherapy Treatment of Type 2 Diabetes Mellitus</title>
        <description>Normal fasting plasma glucose (FPG) levels are being reported. Normal FPG levels range from 70-110 mg/dL. Lower FPG values indicates better clinical outcome, ie. improvement in FPG.</description>
        <time_frame>Baseline up to Week 52 post-dose</time_frame>
        <population>Fasting plasma glucose (FPG) levels were assessed in participants with available data in the Study Extension Set.</population>
        <group_list>
          <group group_id="O1">
            <title>Rivoglitazone 1.0 mg</title>
            <description>Participants with type 2 diabetes mellitus who were administered a Rivoglitazone 1.0 mg tablet once daily for 26 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Rivoglitazone 1.5mg</title>
            <description>Participants with type 2 diabetes mellitus who were administered a Rivoglitazone 1.5 mg tablet once daily for 26 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Pioglitazone 45 mg</title>
            <description>Participants with type 2 diabetes mellitus who were administered a Pioglitazone 45 mg over-encapsulated tablet once daily for 26 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Placebo/ Pioglitazone 45 mg</title>
            <description>Participants with type 2 diabetes mellitus who were administered a Rivoglitazone-matching placebo tablet or a Pioglitazone-matching placebo over-encapsulated tablet once daily for 26 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Fasting Plasma Glucose From Baseline Through Week 52 Extension Period Following Rivoglitazone or Pioglitazone Compared to Placebo as Monotherapy Treatment of Type 2 Diabetes Mellitus</title>
          <description>Normal fasting plasma glucose (FPG) levels are being reported. Normal FPG levels range from 70-110 mg/dL. Lower FPG values indicates better clinical outcome, ie. improvement in FPG.</description>
          <population>Fasting plasma glucose (FPG) levels were assessed in participants with available data in the Study Extension Set.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="64"/>
                <count group_id="O2" value="200"/>
                <count group_id="O3" value="193"/>
                <count group_id="O4" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="64"/>
                    <count group_id="O2" value="200"/>
                    <count group_id="O3" value="193"/>
                    <count group_id="O4" value="27"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="147.4" spread="32.31"/>
                    <measurement group_id="O2" value="152.8" spread="32.32"/>
                    <measurement group_id="O3" value="149.0" spread="36.00"/>
                    <measurement group_id="O4" value="142.5" spread="27.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="21"/>
                    <count group_id="O2" value="48"/>
                    <count group_id="O3" value="38"/>
                    <count group_id="O4" value="7"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="117.8" spread="27.93"/>
                    <measurement group_id="O2" value="116.6" spread="24.12"/>
                    <measurement group_id="O3" value="115.6" spread="19.04"/>
                    <measurement group_id="O4" value="124.9" spread="36.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Fasting Plasma Glucose From Baseline Through Week 52 Extension Period Following Rivoglitazone or Pioglitazone Compared to Placebo as Monotherapy Treatment of Type 2 Diabetes Mellitus</title>
        <description>The change in normal fasting plasma glucose (FPG) levels are being reported. A greater (negative) change from baseline indicates an improvement in FPG.</description>
        <time_frame>Baseline up to 52 weeks post-dose</time_frame>
        <population>Fasting plasma glucose (FPG) was assessed in participants with values at baseline and the extension visit at the end of Cycle 1. Participants who did not have both baseline and Week 52 data were not included in this analysis (n=1 each for Rivoglitazone 1.0 mg and Pioglitazone 45 mg groups).</population>
        <group_list>
          <group group_id="O1">
            <title>Rivoglitazone 1.0 mg</title>
            <description>Participants with type 2 diabetes mellitus who were administered a Rivoglitazone 1.0 mg tablet once daily for 26 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Rivoglitazone 1.5mg</title>
            <description>Participants with type 2 diabetes mellitus who were administered a Rivoglitazone 1.5 mg tablet once daily for 26 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Pioglitazone 45 mg</title>
            <description>Participants with type 2 diabetes mellitus who were administered a Pioglitazone 45 mg over-encapsulated tablet once daily for 26 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Placebo/ Pioglitazone 45 mg</title>
            <description>Participants with type 2 diabetes mellitus who were administered a Rivoglitazone-matching placebo tablet or a Pioglitazone-matching placebo over-encapsulated tablet once daily for 26 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Fasting Plasma Glucose From Baseline Through Week 52 Extension Period Following Rivoglitazone or Pioglitazone Compared to Placebo as Monotherapy Treatment of Type 2 Diabetes Mellitus</title>
          <description>The change in normal fasting plasma glucose (FPG) levels are being reported. A greater (negative) change from baseline indicates an improvement in FPG.</description>
          <population>Fasting plasma glucose (FPG) was assessed in participants with values at baseline and the extension visit at the end of Cycle 1. Participants who did not have both baseline and Week 52 data were not included in this analysis (n=1 each for Rivoglitazone 1.0 mg and Pioglitazone 45 mg groups).</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="48"/>
                <count group_id="O3" value="37"/>
                <count group_id="O4" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-33.8" spread="41.48"/>
                    <measurement group_id="O2" value="-34.2" spread="24.86"/>
                    <measurement group_id="O3" value="-29.5" spread="31.39"/>
                    <measurement group_id="O4" value="-35.9" spread="20.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Drug-Related Treatment-Emergent Adverse Events Reported by ≥1% Participants Following Rivoglitazone or Pioglitazone Compared to Placebo as Monotherapy Treatment of Type 2 Diabetes Mellitus</title>
        <description>Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) that occurred on or after the first dose of double-blind study medication, and ongoing AEs that started prior to the first dose of double-blind study medication and increased in severity on or after the first dose of double-blind study medication.</description>
        <time_frame>Week -2 up to Week 52 post-dose</time_frame>
        <population>Drug-related TEAEs were assessed in the Safety Set which included all randomized participants who received at least 1 dose of study medication and had at least 1 post-baseline safety measurement.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants with type 2 diabetes mellitus who were administered a Rivoglitazone-matching placebo tablet or a Pioglitazone-matching placebo over-encapsulated tablet once daily for 26 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Rivoglitazone 1.0 mg</title>
            <description>Participants with type 2 diabetes mellitus who were administered a Rivoglitazone 1.0 mg tablet once daily for 26 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Rivoglitazone 1.5mg</title>
            <description>Participants with type 2 diabetes mellitus who were administered a Rivoglitazone 1.5 mg tablet once daily for 26 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Pioglitazone 45 mg</title>
            <description>Participants with type 2 diabetes mellitus who were administered a Pioglitazone 45 mg over-encapsulated tablet once daily for 26 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Drug-Related Treatment-Emergent Adverse Events Reported by ≥1% Participants Following Rivoglitazone or Pioglitazone Compared to Placebo as Monotherapy Treatment of Type 2 Diabetes Mellitus</title>
          <description>Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) that occurred on or after the first dose of double-blind study medication, and ongoing AEs that started prior to the first dose of double-blind study medication and increased in severity on or after the first dose of double-blind study medication.</description>
          <population>Drug-related TEAEs were assessed in the Safety Set which included all randomized participants who received at least 1 dose of study medication and had at least 1 post-baseline safety measurement.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="137"/>
                <count group_id="O2" value="269"/>
                <count group_id="O3" value="741"/>
                <count group_id="O4" value="739"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Participants with drug-related TEAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="50"/>
                    <measurement group_id="O3" value="144"/>
                    <measurement group_id="O4" value="134"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Gastritis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Edema</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Edema peripheral</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="14"/>
                    <measurement group_id="O3" value="46"/>
                    <measurement group_id="O4" value="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pitting edema</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="10"/>
                    <measurement group_id="O4" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Weight increased</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="23"/>
                    <measurement group_id="O4" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fluid retention</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Treatment-emergent adverse events (TEAEs) data were assessed from the signing of the informed consent (Week -2) up to 52 weeks post-dose for the duration of the study period.</time_frame>
      <desc>Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) that occurred on or after the first dose of double-blind (DB) study medication, and ongoing AEs that started prior to the first dose of DB study medication and increased in severity on or after the first dose of DB study medication. TEAEs were reported from the Safety Set which included all randomized participants who received at least 1 dose of study medication and had at least 1 post-baseline safety measurement.</desc>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>Participants with type 2 diabetes mellitus who were administered a Rivoglitazone-matching placebo tablet or a Pioglitazone-matching placebo over-encapsulated tablet once daily for 26 weeks.</description>
        </group>
        <group group_id="E2">
          <title>Rivoglitazone 1.0 mg</title>
          <description>Participants with type 2 diabetes mellitus who were administered a Rivoglitazone 1.0 mg tablet once daily for 26 weeks.</description>
        </group>
        <group group_id="E3">
          <title>Rivoglitazone 1.5mg</title>
          <description>Participants with type 2 diabetes mellitus who were administered a Rivoglitazone 1.5 mg tablet once daily for 26 weeks.</description>
        </group>
        <group group_id="E4">
          <title>Pioglitazone 45 mg</title>
          <description>Participants with type 2 diabetes mellitus who were administered a Pioglitazone 45 mg over-encapsulated tablet once daily for 26 weeks.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (10.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="269"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="741"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="739"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="137"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="269"/>
                <counts group_id="E3" subjects_affected="22" subjects_at_risk="741"/>
                <counts group_id="E4" subjects_affected="28" subjects_at_risk="739"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="269"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="741"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="739"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Angina unstable</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="269"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="741"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="739"/>
              </event>
              <event>
                <sub_title>Atrioventricular block</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="269"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="741"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="739"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="269"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="741"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="739"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="269"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="741"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="739"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="269"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="741"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="739"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="269"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="741"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="739"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Basedow's disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="269"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="741"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="739"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Cataract</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="269"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="741"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="739"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Ascites</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="269"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="741"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="739"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="269"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="741"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="739"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="137"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="269"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="741"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="739"/>
              </event>
              <event>
                <sub_title>Gastroesophageal reflux disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="269"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="741"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="739"/>
              </event>
              <event>
                <sub_title>Umbilical hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="269"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="741"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="739"/>
              </event>
              <event>
                <sub_title>Umbilical hernia, obstructive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="269"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="741"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="739"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Hernia obstructive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="269"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="741"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="739"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="137"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="269"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="741"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="739"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Bile duct obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="269"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="741"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="739"/>
              </event>
              <event>
                <sub_title>Cholecystitis acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="269"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="741"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="739"/>
              </event>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="269"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="741"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="739"/>
              </event>
              <event>
                <sub_title>Hepatitis acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="269"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="741"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="739"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="269"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="741"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="739"/>
              </event>
              <event>
                <sub_title>Cystitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="269"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="741"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="739"/>
              </event>
              <event>
                <sub_title>Dengue fever</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="269"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="741"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="739"/>
              </event>
              <event>
                <sub_title>Enterocolitis infectious</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="269"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="741"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="739"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="269"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="741"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="739"/>
              </event>
              <event>
                <sub_title>Hepatitis A</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="269"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="741"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="739"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="269"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="741"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="739"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="269"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="741"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="739"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Alcohol poisoning</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="269"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="741"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="739"/>
              </event>
              <event>
                <sub_title>Ankle fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="269"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="741"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="739"/>
              </event>
              <event>
                <sub_title>Concussion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="269"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="741"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="739"/>
              </event>
              <event>
                <sub_title>Facial bones fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="269"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="741"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="739"/>
              </event>
              <event>
                <sub_title>Hand fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="137"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="269"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="741"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="739"/>
              </event>
              <event>
                <sub_title>Lower limb fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="269"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="741"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="739"/>
              </event>
              <event>
                <sub_title>Road traffic accident</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="269"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="741"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="739"/>
              </event>
              <event>
                <sub_title>Spinal compression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="269"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="741"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="739"/>
              </event>
              <event>
                <sub_title>Traumatic brain injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="269"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="741"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="739"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypoglycemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="137"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="269"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="741"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="739"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Intervertebral disc disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="269"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="741"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="739"/>
              </event>
              <event>
                <sub_title>Intervertebral disc protrusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="269"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="741"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="739"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Adenocarcinoma pancreas</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="269"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="741"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="739"/>
              </event>
              <event>
                <sub_title>Bladder neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="269"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="741"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="739"/>
              </event>
              <event>
                <sub_title>Chronic lymphocytic leukemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="269"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="741"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="739"/>
              </event>
              <event>
                <sub_title>Colon cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="269"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="741"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="739"/>
              </event>
              <event>
                <sub_title>Endometrial cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="269"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="741"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="739"/>
              </event>
              <event>
                <sub_title>Gastric cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="269"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="741"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="739"/>
              </event>
              <event>
                <sub_title>Metastasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="269"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="741"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="739"/>
              </event>
              <event>
                <sub_title>Pancreatic carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="269"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="741"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="739"/>
              </event>
              <event>
                <sub_title>Thyroid neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="269"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="741"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="739"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebral ischemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="269"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="741"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="739"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="269"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="741"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="739"/>
              </event>
              <event>
                <sub_title>Ischemic stroke</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="269"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="741"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="739"/>
              </event>
              <event>
                <sub_title>Status migrainous</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="269"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="741"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="739"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="269"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="741"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="739"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Schizoaffective disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="269"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="741"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="739"/>
              </event>
              <event>
                <sub_title>Suicide attempt</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="269"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="741"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="739"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="269"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="741"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="739"/>
              </event>
              <event>
                <sub_title>Renal colic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="269"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="741"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="739"/>
              </event>
              <event>
                <sub_title>Renal failure acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="269"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="741"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="739"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Polycystic ovaries</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="269"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="741"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="739"/>
              </event>
              <event>
                <sub_title>Uterine polyp</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="269"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="741"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="739"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="269"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="741"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="739"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="269"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="741"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="739"/>
              </event>
              <event>
                <sub_title>Pulmonary thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="269"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="741"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="739"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="269"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="741"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="739"/>
              </event>
              <event>
                <sub_title>Varicose vein</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="269"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="741"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="739"/>
              </event>
              <event>
                <sub_title>Venous thrombosis limb</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="269"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="741"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="739"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>2</frequency_threshold>
        <default_vocab>MedDRA (10.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="56" subjects_at_risk="137"/>
                <counts group_id="E2" subjects_affected="131" subjects_at_risk="269"/>
                <counts group_id="E3" subjects_affected="408" subjects_at_risk="741"/>
                <counts group_id="E4" subjects_affected="374" subjects_at_risk="739"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="137"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="269"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="741"/>
                <counts group_id="E4" subjects_affected="17" subjects_at_risk="739"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="137"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="269"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="741"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="739"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="137"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="269"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="741"/>
                <counts group_id="E4" subjects_affected="17" subjects_at_risk="739"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Edema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="137"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="269"/>
                <counts group_id="E3" subjects_affected="54" subjects_at_risk="741"/>
                <counts group_id="E4" subjects_affected="56" subjects_at_risk="739"/>
              </event>
              <event>
                <sub_title>Pitting edema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="269"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="741"/>
                <counts group_id="E4" subjects_affected="17" subjects_at_risk="739"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="137"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="269"/>
                <counts group_id="E3" subjects_affected="24" subjects_at_risk="741"/>
                <counts group_id="E4" subjects_affected="20" subjects_at_risk="739"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="137"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="269"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="741"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="739"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="137"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="269"/>
                <counts group_id="E3" subjects_affected="40" subjects_at_risk="741"/>
                <counts group_id="E4" subjects_affected="41" subjects_at_risk="739"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="137"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="269"/>
                <counts group_id="E3" subjects_affected="38" subjects_at_risk="741"/>
                <counts group_id="E4" subjects_affected="25" subjects_at_risk="739"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="137"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="269"/>
                <counts group_id="E3" subjects_affected="34" subjects_at_risk="741"/>
                <counts group_id="E4" subjects_affected="30" subjects_at_risk="739"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Weight increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="269"/>
                <counts group_id="E3" subjects_affected="24" subjects_at_risk="741"/>
                <counts group_id="E4" subjects_affected="14" subjects_at_risk="739"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypoglycemia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="137"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="269"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="741"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="739"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="137"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="269"/>
                <counts group_id="E3" subjects_affected="24" subjects_at_risk="741"/>
                <counts group_id="E4" subjects_affected="14" subjects_at_risk="739"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="137"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="269"/>
                <counts group_id="E3" subjects_affected="19" subjects_at_risk="741"/>
                <counts group_id="E4" subjects_affected="22" subjects_at_risk="739"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="137"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="269"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="741"/>
                <counts group_id="E4" subjects_affected="20" subjects_at_risk="739"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="137"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="269"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="741"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="739"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="137"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="269"/>
                <counts group_id="E3" subjects_affected="27" subjects_at_risk="741"/>
                <counts group_id="E4" subjects_affected="27" subjects_at_risk="739"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="137"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="269"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="741"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="739"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="137"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="269"/>
                <counts group_id="E3" subjects_affected="18" subjects_at_risk="741"/>
                <counts group_id="E4" subjects_affected="18" subjects_at_risk="739"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Contact for Clinical Trial Information</name_or_title>
      <organization>Daiichi Sankyo</organization>
      <phone>908-992-6400</phone>
      <email>CTRinfo@dsi.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

